Jennifer Brown, MD, PhD | Authors

Articles

SEQUOIA Study Focuses on High-Risk Deletion 17p Population in CLL

February 14, 2022

Jennifer R. Brown, MD, PhD, discusses the patient population of the SEQUOIA trial of zanubrutinib and venetoclax for patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Emerging Agents in CLL

March 06, 2017

Jennifer Brown, MD, PhD, director of the Chronic Lymphocytic Leukemia Center at the Dana-Farber Cancer Institute, associate professor of Medicine at Harvard Medical School, discusses novel agents under investigation for the treatment of chronic lymphocytic leukemia (CLL).

An Overview of ABT-199 for the Treatment of CLL

February 12, 2014

Jennifer Brown, MD, PhD, Director, Chronic Lymphocytic Leukemia Center, Dana-Farber Cancer Institute, Assistant Professor of Medicine, Harvard Medical School, discusses the Bcl-2 inhibitor ABT-199 for the treatment of patients with CLL.